Trial
NCT02754362
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
MOUNT SINAI HOSPITAL
Condition
Glioblastoma
Intervention
Bevacizumab
Why stopped
Due to personnel changes / departure of Dr. Chi.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-13